Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Greg Rich who wrote (288)	2/16/1999 5:54:00 PM
From: JEB	Read Replies (1) of 2515

Expanded access is expanding a phase II / III trial to more patients, even if they do not meet the profile the company wants for the trial but not including them in the trial group per se. Also, it is allowing patients to opt to keep taking the drug after the initial trial and even in combination as a cocktail formula. The company produces the amount of drug necessary to allow this to happen. GNE is the only company I know who does this currently (All the others are probably worried about liability). IMCL and others need to step up to the plate on this issue. A "no liability" contract, binding to and signed by the family of the patient and/or their heirs, would cover their back sides. -IMO- Good trading, JEB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next